Lukas Kaiser

Lukas Kaiser

Auto-generated profile, based on publicly available information

Lukas Kaiser

Department of Cardiology and Critical Care Medicine, St. George Klinik Asklepios , Hamburg , Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
DCDa-Un Chung
Da-Un Chung
JTJohannes Tauber
Johannes Tauber
LKLukas Kaiser
Lukas Kaiser
ASAndrea Schlichting
Andrea Schlichting
SPSimon Pecha
Simon Pecha
SHSamer Hakmi
Samer Hakmi

2 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
SMSchiavone Marco
Schiavone Marco
AGAlessio Gasperetti
Alessio Gasperetti
JVJulia Vogler
Julia Vogler
Paolo CompagnucciPaolo Compagnucci
Paolo Compagnucci
MLMikael Laredo
Mikael Laredo
GFGiovanni Battista Forleo
Giovanni Battista Forleo
Women have been historically underrepresented in implantable cardioverter-defibrillator (ICD) trials. No data on sex differences regarding subcutaneous ICDs (S-ICD) carriers have been described. Aim of our study was to investigate sex-related differences among unselected S-ICD recipients. Consecutive patients enrolled in the multicentre, international i-SUSI registry were analysed. Comparisons between sexes were performed using a 1:1 propensity matching adjusted analysis for age, body mass index (BMI), left ventricular function, and substrate. The primary outcome was the rate of appropriate shocks during follow-up. Inappropriate shocks and other device-related complications were deemed secondary outcomes. A total of 1698 patients were extracted from the i-SUSI registry; 399 (23.5%) were females. After propensity matching, two cohorts of 374 patients presenting similar baseline characteristics were analysed. Despite similar periprocedural characteristics and a matched BMI, women resulted at lower risk of conversion failure as per PRAETORIAN score (73.4% vs. 81.3%, P = 0.049). Over a median follow-up time of 26.5 [12.7–42.5] months, appropriate shocks were more common in the male cohort (rate/year 3.4% vs. 1.7%; log-rank P = 0.049), while no significant differences in device-related complications (rate/year: 6.3% vs. 5.8%; log-rank P = 0.595) and inappropriate shocks (rate/year: 4.3% vs. 3.1%; log-rank P = 0.375) were observed. After controlling for confounders, sex remained significantly associated with the primary outcome (aHR 1.648; CI 0.999–2.655, P = 0.048), while not resulting predictor of inappropriate shocks and device-related complications. In a propensity-matched cohort of S-ICD recipients, women are less likely to experience appropriate ICD therapy, while not showing higher risk of device-related complications. ClinicalTrials.gov Identifier: NCT0473876.

1 June 2021 in Heart Rhythm
Verified
Journal Article
Closed access
DCDa-Un Chung
Da-Un Chung
LMLisa Müller
Lisa Müller
TUTimm Ubben
Timm Ubben
YYYalin Yildirim
Yalin Yildirim
JPJohannes Petersen
Johannes Petersen
SHSamer Hakmi
Samer Hakmi

1 January 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
FQFabio Quartieri
Fabio Quartieri
YBYong-Soo Baek
Yong-Soo Baek
JPJong-Sung Park
Jong-Sung Park
TKTae Hoon Kim
Tae Hoon Kim
KHKazunari Honma
Kazunari Honma
LKLukas Kaiser
Lukas Kaiser
Background: The detection of atrial fibrillation (AF) after a cryptogenic stroke (CS) carries important therapeutic implications. In this study, we aimed to accurately assess the incidence of AF among CS subjects by using an insertable cardiac monitor (ICM). Methods: A prospective, single-arm, multicentre registry was conducted to identify AF in 155 CS subjects using the Confirm Rx ICM (Abbott, California, USA) across 20 global sites. Inclusion criteria comprised participants aged 40 years or older who had experienced CS within a 90-day window. At each follow-up visit, expert electrophysiologists reviewed and adjudicated ICM detected AF episodes. The primary endpoint was the cumulative incidence of true device-detected AF (lasting more than 30 s) at 6 months, evaluated with Kaplan-Meier methods. Results: AF incidence was 21.3% (95% CI 15.3% to 29.1%) at 6 months, increasing to 48.8% (95% CI 34.7% to 64.9%) at 24 months. Subjects with AF detection experienced an average of 50.9 true AF episodes per subject per year. The median time from implantation to AF detection (>30 s) was 72 days (IQR 7–261). Among subjects with 30 s AF detection, anticoagulation therapy was initiated in 65.2% (30/46) of subjects. Oral anticoagulation medication was prescribed in 8.3% (9/109) of subjects without AF. Recurrent ischaemic stroke or transient ischaemic attack occurred in 5 subjects (3.2%, 5/155). Conclusion: These results show that ICM-driven long-term continuous AF monitoring is associated with high diagnostic yield in CS subjects. Trial registration number: NCT03505801

30 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
SMSchiavone Marco
Schiavone Marco
AGAlessio Gasperetti
Alessio Gasperetti
Paolo CompagnucciPaolo Compagnucci
Paolo Compagnucci
JVJulia Vogler
Julia Vogler
MLMikael Laredo
Mikael Laredo
GFGiovanni Battista Forleo
Giovanni Battista Forleo
Catheter ablation (CA) of ventricular tachycardia (VT) has become an important tool to improve clinical outcomes in patients with appropriate transvenous implantable cardioverter defibrillator (ICD) shocks. The aim of our analysis was to test whether VT ablation (VTA) impacts long-term clinical outcomes even in subcutaneous ICD (S-ICD) carriers. International Subcutaneous Implantable Cardioverter Defibrillator (iSUSI) registry patients who experienced either an ICD shock or a hospitalization for monomorphic VT were included in this analysis. Based on an eventual VTA after the index event, patients were divided into VTA+ vs. VTA− cohorts. Primary outcome of the study was the occurrence of a combination of device-related appropriate shocks, monomorphic VTs, and cardiovascular mortality. Secondary outcomes were addressed individually. Among n = 1661 iSUSI patients, n = 211 were included: n = 177 experiencing ICD shocks and n = 34 hospitalized for VT. No significant differences in baseline characteristics were observed. Both the crude and the yearly event rate of the primary outcome (5/59 and 3.8% yearly event rate VTA+ vs. 41/152 and 16.4% yearly event rate in the VTA−; log-rank: P value = 0.0013) and the cardiovascular mortality (1/59 and 0.7% yearly event rate VTA+ vs. 13/152 and 4.7% yearly event rate VTA−; log-rank P = 0.043) were significantly lower in the VTA + cohort. At multivariate analysis, VTA was the only variable remaining associated with a lower incidence of the primary outcome [adjusted hazard ratio 0.262 (0.100–0.681), P = 0.006]. In a real-world registry of S-ICD carriers, the combined study endpoint of arrhythmic events and cardiovascular mortality was lower in the patient cohort undergoing VTA at long-term follow-up. NCT0473876.

24 May 2024 in EP Europace
Verified
Journal Article
Open access
ASA Schlichting
A Schlichting
DCDa-Un Chung
Da-Un Chung
ERE Rexha
E Rexha
LKL Kaiser
L Kaiser
SPSimon Pecha
Simon Pecha
SHSamer Hakmi
Samer Hakmi
Background: Transvenous lead extraction (TLE) in patients with cardiac implantable electronic devices has become a well-established therapy for patients with lead complications. However, there is limited information on specific outcomes for patients with right-sided leads compared to patients with left-sided leads undergoing TLE. Aim: The aim of this study was to analyze patient characteristics, procedural outcomes as well as adverse events and mortality of patients with right-sided leads undergoing TLE with the excimer laser sheath as a first line therapy. Methods: We performed a subgroup analysis of all reported patients in the GALLERY (GermAn Laser Lead Extraction RegistrY) with unilateral right-sided leads (Group 1) or unilateral left-sided leads (Group 2). Results: 2438 patients with unilateral leads were analyzed. 750 patients were in Group 1 and 1688 patients were in Group 2. Patients in Group 1 were older (71.1 ± 13.9 vs. 66.5 ± 13.6; p < 0.001), more patients were female (31.7% vs. 22.1%, p < 0.001), had a lower body-mass-index (26.8 ± 4.5 vs. 27.2 ± 4.7; p=0.03) and more patients were pacemaker dependent (44.9% vs. 25.4%, p< 0.001). The primary indication for TLE was local infection (46.0% vs. 30.6%, p< 0.001) in Group 1 and lead dysfunction (20.0% vs. 36.1%, p< 0.0001) in Group 2. The frequency of TLE for systemic infection was indifferent between groups (28.9% vs. 27.6%, p=0.532). The most common device to be extracted were pacemakers (80.1% vs. 22.7%, p< 0.001) in Group 1 and implantable cardioverter-defibrillators (ICD) (9.7 vs. 45.3%, p< 0.001) and cardiac resynchronization therapy devices (CRT) (9.6 vs. 31.5%); p< 0.001) in Group 2. The mean number of total leads was not different between groups (2.4 ± 0.9 for Group 1 vs. 2.3 ± 1.0 for Group 2; p=0.98), however median lead dwell time (120 vs. 85 months, p< 0.001), patients with abandoned leads (32.0% vs. 25.9%; p=0.0022) and the use of additional extraction tools (8.4% vs. 5.7%, p=0.016) were significantly higher in Group 1. Patients with right-sided leads had a longer median hospital stay (10 vs. 9 [5; 15] p=0.001). Complete procedural success was higher in patients Group 2 (89.1 vs. 93.1%, p=0.001) but there was no difference in clinical success rates (97.7% vs. 98.0%, p=0.74). There was no difference in overall complication rates (4.3% vs. 4.2%, p=0.945). Neither procedure related mortality (0.3% vs. 0.7%, p=0.2940) nor all-cause mortality (3.5% vs. 3.4%, p=0.9101) differed between groups. Conclusion: TLE procedures in patients with right-sided leads showed a lower procedural success rate and a higher need of additional tools. This patient group was older, more often pacemaker dependent and had a higher number of abandoned leads. Despite different patient and lead characteristics, there were no differences in clinical success-rates, procedure related complications or all-cause mortality between groups.